The final study involved an assessment of the acute effect of AOD9604 and a β3-AR agonist (BRL37344) on energy expenditure, fat oxidation, and glucose oxidation in WT andβ 3-KO mice. When AOD9604 or BRL37344 were administered to WT mice, an acute increase in fat oxidation and energy expenditure occurred, with an associated reduction in glucose oxidation (Fig. 6A). The effect plateaued 18 min following injection and remained stable for the duration of the experiment. The response to the two compounds was very similar, despite the fact we have previously shown that AOD9604 does not directly interact with the β3-AR as demonstrated by ligand binding studies (11). This clear separation of pathways was further confirmed in Fig. 6B in which AOD9604 clearly increases fat oxidation and energy expenditure inβ 3-KO mice, whereas BRL37344 does not. The KO mice neither decrease their glucose oxidation in response to AOD9604 nor show a prolonged increase in fat oxidation and energy expenditure in response to AOD9604.

Follow the same routine as shown above for "intermediate" persons. However, as soon as possible after your weight training you should also inject 200mcg of PEG-MGF (IGF-1e) and/or 50mcg of IGF-1 LR3 preferably into a muscle (although due to the long half-life of both products, sub-q injections are also acceptable). If injecting intramuscularly, you should make sure that the muscle you are injecting into is not covered by a thick layer of fat. Usually due to the length of insulin syringe needles, injections are therefore limited to the biceps for most persons.
However, it cannot be legally imported without a special permit under the strict Special Access Scheme, which requires a doctor to apply to the TGA for permission to treat a particular patient with the drug, including describing the specific clinical need. ''There have been no applications under the SAS for AOD-9604,'' the TGA spokeswoman confirmed on Thursday.
Tβ4 has been used at our clinic with a great deal of success in patients suffering from Lyme disease or other infectious and/or inflammatory conditions. Tβ4 is very well tolerated and has not been found to cause any significant side effects. It can be taken on its own or in conjunction with an existing therapy, making it a versatile and valuable drug.
A large difference between steroid hormones and peptide hormones is that some steroid hormones exhibit oral activity, in that they can be active after they are taken by mouth. However, many peptide hormones are digested in the same way as proteins. They are broken down into amino acids in the digestive system, which means they no longer have the bioactivity of their parent compound. Consequently, they may require administration through injections.
AOD9604, a synthetic fragment of hGH consisting of the amino acid residues 177–191 with the addition of a tyrosine residue to the N-terminus was prepared with solid-phase synthesis procedure and purified with reverse-phase HPLC methodology in our laboratories (13). The structure of the peptide analog was verified with mass spectrometry and amino acid analysis. The hGH was a gift of Professor Michael Waters (University of Queensland, Brisbane, Australia). BRL37344 (β3-AR agonist) was a gift from Dr. Jon Arch (SmithKline Beecham, Harlow, UK).

Obesity affects as many as one in five adults in developed countries. Metabolic estimates that the potential worldwide market for effective obesity drugs is as much as $20 billion, far more than the current market of $1.5 billion. This is partly due to the potential need for chronically obese people to take obesity drugs such as AOD9604 and also because patients are put off using currently available drugs because of their marginal efficacy or side-effects.

An OGTT was performed at screening and after 12 and 24 weeks of treatment. At these visits blood samples for assessment of glucose and insulin were collected immediately prior to and 2 hours after an oral glucose load. After 12 weeks the overall change in pre-load glucose was -0.02 units and there were no significant differences between the randomized treatment groups (P = 0.73488). The changes in pre-load glucose in the placebo group differed by -0.08, -0.06, and -0.07 units from those obtained in the AOD9604 0.25 mg, 0.5 mg, and 1 mg treatment groups, respectively; none of these differences were statistically significant. Similar results have been obtained after 24 weeks of treatment. The overall change in pre-load glucose after 24 weeks treatment was 0.04 units, and there were no significant differences among the treatment groups (P = 0.62787). Estimated differences from placebo in change in pre-load glucose were -0.03, 0.02, and 0.06 units for the AOD9604 0.25 mg, 0.5 mg, and 1 mg treatment groups, respectively; none of these differences were statistically significant.
Five public submissions were received. Many of the submissions referred to the article published in the New England Journal of Medicine (NEJM) when giving their reasons for either supporting or rejecting the proposal. Some submissions also noted that a similar proposal is to be considered by an upcoming meeting of the Medicines Classification Committee (MCC) in New Zealand.
One more way for growth hormone to help with fat loss is that this sustains the levels of blood glucose through inhibiting glucose uptake to the peripheral cells, reducing the glucose oxidation for the energy in cells and thus boosting the production of the glucose in the cells from amino acids and fats. The blood’s free fatty acids from lipolysis also partially obstruct the insulin receptors on the cell membranes, reducing insulin’s effectiveness in triggering glucose removal from the blood that causes decreased sensitivity to insulin or insulin resistance. These will then result to fat loss, particularly from the difficult to move intra-abdominal storages of fat.
Obesity is the Western World’s most common health problem, and has reached epidemic proportions according to the World Health Organisation. More than 20% of the adult population in developed countries are obese – more than 300 million adults worldwide. In addition, more than 50% of adults in developed countries are overweight. Obesity is associated with other health-related problems such as heart disease, cancer and diabetes.
In vitro studies by Metabolic Collaborators showed that AOD9604 enhances the differentiation of adipose mesenchymal stem cells into bone, promotes proteoglycan and collagen production in isolated bovine chondrocytes, and promotes differentiation of myoblasts into C2C12 cells. These effects induced by AOD9604 are similar to those required for the repair of bone, cartilage, and muscle, all of which are affected in OA. To the best of our knowledge, no study has compared the effects of GH and HA intra-articular injections on OA. A previous study showed the effects of intra-articular GH injection on articulophyseal cartilage regeneration in the knees of rabbits [9]. Our study showed that the groups that received AOD9604 or HA injection had better outcomes in terms of morphological and histolopathological findings, as well as a lowered duration of lameness than the group that received saline injections, although there are no significant differences between the two groups. In addition, our study revealed that the groups that received combined injections of AOD9604 and HA showed better outcomes than the groups that received AOD9604 or HA alone. The apparently synergistic effect of combined injections is thought to indicate that intra-articular injection of HA may have a chondrocyte-protective role, and the AOD9604 could help recapitulate the developmental cascades which regrows a segment of the articular cartilage in a joint. Our results are consistent with those of a previous study [8] that combined the injection of HA with recombinant human GH and found that the combination is more effective than HA injection alone.
The biggest negative, and this is a big one, is that AOD9604 has undergone very rigorous scientific testing, and has been found to have no effect in humans (3). When AOD9604 was first developed, it showed significant promise as a weight loss treatment. A special strain of obese mice supplemented with the peptide showed a reduction in weight, increased fat oxidation, and raised plasma glycerol, which are indicators of lipolysis, or fat burning (5). Subsequent studies in obese mice and rats attempted to show that the peptide works to burn fat in the same way as human growth hormone, but found that this was not the case, meaning that the fact this peptide resembled hGH was meaningless. Scientists were unable to determine how this peptide was working in mice (6).
The most common goal of people in the health and fitness world is to lose weight. Not only do hundreds of millions of people go on diets to try and lose weight every year, but they want to lose weight as fast as possible. It’s no wonder the weight loss industry is a $20 billion industry, with the sales of books, diet drugs, and weight-loss surgeries fueling revenue as people try and lose unwanted weight once and for all.
17 Arora P, Wu C, Khan AM, Bloch DB, Davis‐Dusenbery BN, Ghorbani A, Spagnolli E, Martinez A, Ryan A, Tainsh LT, Kim S, Rong J, Huan T, Freedman JE, Levy D, Miller KK, Hata A, Del Monte F, Vandenwijngaert S, Swinnen M, Janssens S, Holmes TM, Buys ES, Bloch KD, Newton‐Cheh C, Wang TJ. Atrial natriuretic peptide is negatively regulated by microrna‐425. J Clin Invest. 2013;123:3378–3382.CrossrefMedlineGoogle Scholar
Strengths of our study include the serial physiologic assessments before and after bariatric surgery. The gastric bypass procedure ensured a large degree of weight loss (≈27% mean change in BMI), while the administration of normal saline provided an acute stimulus for eliciting acute natriuretic peptide responses. Thus, we were able to compare the relative effects of weight loss and saline infusion, with each individual serving as his or her own control. This study design minimizes confounding from sources of natriuretic peptide variation that might correlate with BMI. We performed the post‐surgical assessment 6 months after surgery to ensure that acute hemodynamic changes from surgery had resolved and patients had attained most of their expected weight loss. Mitral annular early diastolic (e′) velocity at the lateral annulus has been accepted as an index of diastolic function24, 25 and we had significant improvement in e′ suggesting improvement in myocardial relaxation. Our echocardiographic findings are in accordance with the recently published meta‐analysis demonstrating benefits of bariatric surgery on diastolic function.26
GHRP + GHRH (twice per day) ◦Inject your GHRP + GHRH peptides together in the same syringe (ensuring you have not consumed any food/beverages for at least 1 hour before, an optimal time would be first thing in the morning). ◦Ingest a protein only or protein and carbohydrate meal afterward to create an insulin spike. ◦Do weight training in the hours afterwards. ◦at least 1 hour after your dinner (or last meal of the day), take your second GHRP + GHRH injection. ◦If you are trying to control your body fat then have a protein only meal 20-30 minutes afterwards, otherwise a protein/carbohydrate meal will create a better insulin spike.

CJC-1295 10mg (Up to 10 Weeks): Started Wednesday 21 st September 2016 weight 122 kilo. Belly measurement 122cm Thursday 22nd September Weight @ 3pm 118.5 kilo Belly Measurement 117cm Morning and night 3 pumps Stacking with CJC1295 injectable. Lots of energy feel great aches and pains starting to subside.I will be doing a few more courses in the near future. THANKS Peptideclinics.com.au Awesome products. Shane Ridley
Another very positive benefit of CJC1295 is its ability to promote slow wave sleep. Slow wave sleep (SWS) is also known as deep sleep and is the portion of sleep responsible for the highest level of muscle growth and memory retention. SWS is decreased significantly in older adults and also with people who tend to exercise later in the evening.  This peptide has a benefit to side effect ratio that exceeds all others currently being legally sold and would make a great addition to ones training regimen or post cycle therapy.
I stopped the colostrum and my ” symptoms ” subsided, seems I have a moderately enlarged prostate which doesn’t run in my family on either side, my question is could the colostrum possibly cause the prostate to enlarge due to the igf-1 at a certain age,? due to a possible decline in testosterone, or could the benefits of colostrum outweigh the prostate issue?

If muscle gain is not what you’re looking to gain, then the best place to start is by getting your hands on some CJC-DAC and administer at 2-5mg per week. CJC-1295 with or without DAC is suitable. An equally effective alternative is GW501516. Peptide Clinics Australia recommend Oxytocin for weight loss highly and they’ve had amazing results from patients that have been prescribed this.
•If injecting just a GHRP or GHRH product on their own, avoid eating/drinking anything high in fat for 3 hours before your injection and anything high in carbohydrates for 2 hours before (i.e. always do your injection on an empty stomach), otherwise the amount of GH release they cause may be significantly blunted leading to poor results. •If injecting both a GHRP and GHRH together (e.g. 100mcg of both GHRP-6 and Modified GRF 1-29) studies have proven that their ability to release GH returns to full-strength as little as 1 hour (60 minutes) post-meal. This gives users greater flexibility with their meal timings, especially since consuming sufficient calories is so critical to building muscle. •Whether injecting GH peptides alone or along with others, always wait at least 20 minutes after your injection before consuming anything. Once at least 20 minutes has passed, consume a food/beverage high in protein and/or carbohydrates to stimulate an insulin spike (if you inject in the morning and around your workout, this meal/shake should be high protein and high carbohydrates, if you inject at night this consumption should be protein only as protein is sufficient enough to spike insulin, but without the negative impact on fat gain which carbohydrates can contribute to).
In ob/ob mice, both AOD9604 and hGH reduced both white and brown adipose tissue mass and increased β3-AR RNA expression. This suggested that an elevation inβ 3-AR RNA expression is associated with increased fat metabolism and a reduction in the fat tissue mass in the ob/ob mouse model. Obese mice have lower levels ofβ 3-AR expression in their adipose tissues than lean mice, shown in this study and others (14). The ability of AOD9604 and hGH to increase the level ofβ 3-AR RNA expression in obese mice to a level that is comparable to those in lean mice is an exciting finding. However, it must also be considered that both hGH and AOD9604 may influence the expression of other members of the adrenergic pathway, such as the β1-ARs, hormonesensitive lipase, and signaling proteins, which are all expressed in adipose tissue and associated with lipolysis. The importance of the change inβ 3-AR expression with AOD9604 and hGH in humans is not established and will depend on the use of potent and selectiveβ 3-AR agonists that are active at the human receptor.
Between 2001 and 2006 six human clinical trials with the hexadecapeptide AOD9604 have been performed, 893 healthy, in all but one study, clinically obese adults participated in these studies and are the basis of this safety evaluation. The details of the individual studies are listed in supplementary data. The first 3 studies were dose-escalating studies investigating the acute effects of various dosages and two application routes (i.v. and oral) in healthy or obese male subjects. These single dose studies were followed by a 7-day multiple dose study (METAOD004) as well as two long-term clinical trials (METAOD005 and METAOD006) where the safety and tolerability of chronic oral treatment with AOD9604 was investigated.
These results also demonstrate that, unlike hGH, AOD9604 has no negative effect on carbohydrate metabolism. This was previously demonstrated in mice. Chronic administration of hGH to ob/ob mice depressed glucose oxidation and increase plasma glucose levels. AOD9604 had no such effects, no changes in circulating plasma glucose in either lean nor obese ob/ob mice have been observed [20]. AOD9604 did not cause hyperglycemia or affect insulin sensitivity in rats and mice [18, 20].
Subjects were excluded if they had any of the following: history of myocardial infarction, heart failure, or left ventricular (LV) ejection fraction <50%, greater than mild valvular stenosis or regurgitation or any regional wall motion abnormalities by cardiac imaging, chronic renal failure or serum creatinine ≥3.0 mg/dL, atrial fibrillation, diabetes mellitus requiring insulin therapy, systolic blood pressure ≥170 mm Hg or diastolic blood pressure ≥100 mm Hg at the most recent weight center visit, a history of current loop or thiazide diuretic use, a history of obstructive lung disease, or thyroid dysfunction. Female subjects who were pregnant or planned to become pregnant within 6 months were also excluded. The Partners Human Research Committee approved the protocol. All subjects provided informed consent.
Another side effect of the CJC-1295 is acromegaly, since it helps in increasing the levels of the growth hormone. Acromegaly is a condition where extra growth hormone is released even after the internal organs and the skeleton have finished growing. This causes thickening of the skin, deepening of voice, enlargement of jaws, and slurring of speech. Another effect of acromegaly is the swelling of the soft tissue in the internal organs. This could result in the weakening of the muscles of the internal organs, like the heart. This was tested during the phase 2 testing of CJC-1295.
Colostrum: The very early form of milk secreted late in pregnancy and in the first few days after birth, colostrum contains a complex mixture of nutrients, antibodies (to build immunity) and growth factors (to stimulate gut development) which are important to a newborn’s health and development, though its effects in adults are less clear. There’s little evidence that colostrum consumption (typically cow colostrum) improves the immune status of athletes. While not directly banned, colostrum could stimulate Insulin-Like Growth Factor-1 (IGF-1) secretion. IGF-1 is banned, but stimulation of its secretion by nutritional supplements is a grey area.
Some athletes and bodybuilders help their body with the weight loss process using peptides like GHRP-2, a growth hormone releasing peptide. GHRP-2 has been shown to increase bone density and cellular repair, increase lean body mass, decrease body fat, and improve sleep. Combined with a reduced calorie diet and exercise program, GHRP-2 can help you achieve your weight loss and fitness goals faster.
Within all clinical trials the subjects underwent physical examination. The vital signs were observed, laboratory parameters were analyzed (hematology; biochemistry, urinalysis, lipid analysis), and ECG were measured before and after treatment (or in between and follow-up depending on the duration of the study). All subjects were interviewed at each visit with regard to any adverse events (AEs) they had experienced since the previous visit. The causality of AEs (namely their relationship to trial treatment) was assessed by the Principal Investigator. Special attention was made to on the evaluation of Serious Adverse Events (SAE).

Peptide supplementation is fast becoming Australia’s solution to a variety of health, fitness, and age-related concerns. Peptides have been around long before the recent media brought it to our attention through use in elite sport. The simple science of amino acids linked together, via peptide bonds, brings to life this now common word—peptides. Some of the benefits that peptides can assist you with during your journey to health and wellbeing include:
×